RenovoRx

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Los Altos, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cortexyme Inc

Grab Holdings Ltd

NuZee, Inc.

Pioneer Power Solutions

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard

Newegg Commerce

TDH Hlds

PPSI, NUZE, and three other stocks are ranked highly in Fintel's Short Squeeze Screener. All three names have a score higher than 96.

Short Squeeze Stocks: PPSI, NUZE and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC) are two high-profile examples of short squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Pioneer Power Tops List Along With Newegg, Nuzee And More

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September 30, 2021. “The third quarter of 2021 marked an important juncture in the growth of our company as we completed our IPO in late August and our seventh U.S. patent was issued for our RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion) therapy platform. Our team remains patient

RenovoRx Announces Third Quarter 2021 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will be presenting an ePoster at the 2021 Pancreas Club Annual Meeting being held virtually on November 11-12, 2021. The poster describes the RR2 Observational Registry Study, which used RenovoRx's novel therapy platform, RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion), to deliver gemcitabine, an approved chemotherapeutic agent, i

RenovoRx Announces Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting

The stock price of RenovoRx Inc (NASDAQ: RNXT) increased by over 130% during intraday trading today. This is why it happened.

RenovoRx (RNXT) Stock: Why The Price Surged Over 130% Today

RenovoRx (RNXT) stock is rocketing higher today thanks to a presentation of data at a medical conference yesterday evening. The post RNXT Stock Alert: 5 Things to Know as RenovoRx Soars 100%+ Today appeared first on InvestorPlace.

RNXT Stock Alert: 5 Things to Know as RenovoRx Soars 100%+ Today

MIAMI & LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its novel therapy platform, RenovoTAMPTM (RenovoRx Trans-Arterial Micro-Perfusion), will be highlighted during a presentation by expert panelist, Dr. Ripal Gandhi, at the Miami Cancer Institute's New Advances in the Management of Pancreatic Cancer CME course this evening. Dr. Gandhi, a Principal Investigator in RenovoRx's ongoing Phase

Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer

RenovoRx (RNXT) stock is running higher on Tuesday following news that the U.S. Food and Drug Administration granted it new 501(k) clearance. The post RNXT Stock: The FDA News That Has Biotech Company RenovoRx Rocketing Higher Today appeared first on InvestorPlace.

RNXT Stock: The FDA News That Has Biotech Company RenovoRx Rocketing Higher Today

The stock price of RenovoRx Inc (NASDAQ: RNXT) increased by over 50% pre-market. This is why it happened.

RNXT Stock: Over 50% Increase Pre-Market Explanation

The FDA has granted a new 510(k) clearance to RenovoRx Inc's (NASDAQ:RNXT) RenovoCath Delivery System.  The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.

See Why RenovoRx Stock Is Shooting Higher On Tuesday

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ --  RenovoRx , Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System.

RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors

RenovoRx has filed to raise $22.2 million in an IPO. The firm is in Phase 3 clinical trials for its novel drug delivery system for cancer treatments.

RenovoRx Proposes Terms For $22 Million IPO

News for RenovoRx Stock (RNXT)